Jeffrey L. Cummings (ed.)
Progress in Neurotherapeutics and Neuropsychopharmacology
Volume 3, 2008
Herausgeber: Cummings, Jeffrey L.
Jeffrey L. Cummings (ed.)
Progress in Neurotherapeutics and Neuropsychopharmacology
Volume 3, 2008
Herausgeber: Cummings, Jeffrey L.
- Broschiertes Buch
- Merkliste
- Auf die Merkliste
- Bewerten Bewerten
- Teilen
- Produkt teilen
- Produkterinnerung
- Produkterinnerung
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Andere Kunden interessierten sich auch für
- Jeffrey L. Cummings (ed.)Progress in Neurotherapeutics and Neuropsychopharmacology232,99 €
- Jeffrey L. Cummings (ed.)Progress in Neurotherapeutics and Neuropsychopharmacology201,99 €
- Progress in Neurotherapeutics and Neuropsychopharmacology72,99 €
- Progress in Neurotherapeutics and Neuropsychopharmacology83,99 €
- Daniel R. DietrichHistology Endocrine w/website188,99 €
- Progress In Psychobiology and Physiological Psychology250,99 €
- Gerald LangnerThe Neural Code of Pitch and Harmony116,99 €
-
-
-
An essential update of recent clinical trials in the management of neurological and neuropsychiatric disorders.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Hinweis: Dieser Artikel kann nur an eine deutsche Lieferadresse ausgeliefert werden.
Produktdetails
- Produktdetails
- Verlag: Cambridge University Press
- Seitenzahl: 312
- Erscheinungstermin: 15. März 2009
- Englisch
- Abmessung: 244mm x 170mm x 17mm
- Gewicht: 542g
- ISBN-13: 9780521115612
- ISBN-10: 0521115612
- Artikelnr.: 26203784
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
- Verlag: Cambridge University Press
- Seitenzahl: 312
- Erscheinungstermin: 15. März 2009
- Englisch
- Abmessung: 244mm x 170mm x 17mm
- Gewicht: 542g
- ISBN-13: 9780521115612
- ISBN-10: 0521115612
- Artikelnr.: 26203784
- Herstellerkennzeichnung
- Books on Demand GmbH
- In de Tarpen 42
- 22848 Norderstedt
- info@bod.de
- 040 53433511
Contributors; 1. Progress in neurotherapeutics and neuropsychopharmacology
Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of
stroke Antonio Culebras, Javier Borja and Julián García-Rafanell; 3. The
Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4.
Use of Selegiline as monotherapy and in combination with Levodopa in the
management of Parkinson's disease: perspectives from the MONOCOMB study
Sven E. Pålhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in
advanced Parkinson's disease: review of a randomised, double-blind,
placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and
Rajesh Pahwa; 6. Insulin resistance and Alzheimer's disease:
pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7.
Targeting Amyloid with Tramiprosate in patients with mild-to-moderate
Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong
and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated
in acute cluster headache: a randomized placebo-controlled double-blind
crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of
immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn,
Catherine Meyer, Neil Allen and Dennis O'Brien; 10. Tetrathiomolybdate
versus Trientine in the initial treatment of neurologic Wilson's disease
George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael
Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink,
Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized
clinical trials of Pregabalin for neuropathic pain: methods, results, and
implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma
and James P. Young; 12. Effect of Methylphenidate in patients with acute
traumatic brain injury: a randomized clinical trial Hossein A. Khalili and
Kamyar Keramatian; 13. Improvement in speeded cognitive processing after
anti-epileptic drug withdrawal - a controlled study in mono-therapy
patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad;
14. A randomized-controlled trial of bilateral rTMS for treatment-resistant
depression Paul B. Fitzgerald; 15. Serotonin related genes affect
antidepressant treatment in obsessive-compulsive disorder F. Van
Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome
and results from the first placebo-controlled trial of treatment, with the
SSRI medication, Sertraline: implications for clinical practice John P.
O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17.
Modafinil: a candidate for pharmacotherapy of negative symptoms in
schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to
treatment of schizophrenia by enhancing N-methyl-D-aspartate
neurotransmission Guochuan Emil Tsai; Subject index; Author index.
Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of
stroke Antonio Culebras, Javier Borja and Julián García-Rafanell; 3. The
Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4.
Use of Selegiline as monotherapy and in combination with Levodopa in the
management of Parkinson's disease: perspectives from the MONOCOMB study
Sven E. Pålhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in
advanced Parkinson's disease: review of a randomised, double-blind,
placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and
Rajesh Pahwa; 6. Insulin resistance and Alzheimer's disease:
pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7.
Targeting Amyloid with Tramiprosate in patients with mild-to-moderate
Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong
and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated
in acute cluster headache: a randomized placebo-controlled double-blind
crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of
immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn,
Catherine Meyer, Neil Allen and Dennis O'Brien; 10. Tetrathiomolybdate
versus Trientine in the initial treatment of neurologic Wilson's disease
George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael
Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink,
Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized
clinical trials of Pregabalin for neuropathic pain: methods, results, and
implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma
and James P. Young; 12. Effect of Methylphenidate in patients with acute
traumatic brain injury: a randomized clinical trial Hossein A. Khalili and
Kamyar Keramatian; 13. Improvement in speeded cognitive processing after
anti-epileptic drug withdrawal - a controlled study in mono-therapy
patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad;
14. A randomized-controlled trial of bilateral rTMS for treatment-resistant
depression Paul B. Fitzgerald; 15. Serotonin related genes affect
antidepressant treatment in obsessive-compulsive disorder F. Van
Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome
and results from the first placebo-controlled trial of treatment, with the
SSRI medication, Sertraline: implications for clinical practice John P.
O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17.
Modafinil: a candidate for pharmacotherapy of negative symptoms in
schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to
treatment of schizophrenia by enhancing N-methyl-D-aspartate
neurotransmission Guochuan Emil Tsai; Subject index; Author index.
Contributors; 1. Progress in neurotherapeutics and neuropsychopharmacology
Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of
stroke Antonio Culebras, Javier Borja and Julián García-Rafanell; 3. The
Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4.
Use of Selegiline as monotherapy and in combination with Levodopa in the
management of Parkinson's disease: perspectives from the MONOCOMB study
Sven E. Pålhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in
advanced Parkinson's disease: review of a randomised, double-blind,
placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and
Rajesh Pahwa; 6. Insulin resistance and Alzheimer's disease:
pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7.
Targeting Amyloid with Tramiprosate in patients with mild-to-moderate
Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong
and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated
in acute cluster headache: a randomized placebo-controlled double-blind
crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of
immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn,
Catherine Meyer, Neil Allen and Dennis O'Brien; 10. Tetrathiomolybdate
versus Trientine in the initial treatment of neurologic Wilson's disease
George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael
Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink,
Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized
clinical trials of Pregabalin for neuropathic pain: methods, results, and
implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma
and James P. Young; 12. Effect of Methylphenidate in patients with acute
traumatic brain injury: a randomized clinical trial Hossein A. Khalili and
Kamyar Keramatian; 13. Improvement in speeded cognitive processing after
anti-epileptic drug withdrawal - a controlled study in mono-therapy
patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad;
14. A randomized-controlled trial of bilateral rTMS for treatment-resistant
depression Paul B. Fitzgerald; 15. Serotonin related genes affect
antidepressant treatment in obsessive-compulsive disorder F. Van
Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome
and results from the first placebo-controlled trial of treatment, with the
SSRI medication, Sertraline: implications for clinical practice John P.
O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17.
Modafinil: a candidate for pharmacotherapy of negative symptoms in
schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to
treatment of schizophrenia by enhancing N-methyl-D-aspartate
neurotransmission Guochuan Emil Tsai; Subject index; Author index.
Jeffrey L. Cummings; 2. Trifusal versus aspirin for the prevention of
stroke Antonio Culebras, Javier Borja and Julián García-Rafanell; 3. The
Argatroban and tPA stroke study Andrew D. Barreto and James C. Grotta; 4.
Use of Selegiline as monotherapy and in combination with Levodopa in the
management of Parkinson's disease: perspectives from the MONOCOMB study
Sven E. Pålhagen and Esa Heinonen; 5. Ropinirole 24-h prolonged release in
advanced Parkinson's disease: review of a randomised, double-blind,
placebo-controlled study (EASE PD - adjunct study) Kelly E. Lyons and
Rajesh Pahwa; 6. Insulin resistance and Alzheimer's disease:
pathophysiology and treatment G. Stennis Watson and Suzanne Craft; 7.
Targeting Amyloid with Tramiprosate in patients with mild-to-moderate
Alzheimer's disease P. S. Aisen, R. Briand, D. Saumier, J. Laurin, A. Duong
and D. Garceau; 8. Intranasal Zolmitriptan is effective and well-tolerated
in acute cluster headache: a randomized placebo-controlled double-blind
crossover study E. Cittadini and P. J. Goadsby; 9. Optimal dosing of
immunomodulating drugs: a dose-comparison study of GA in RRMS Daniel Wynn,
Catherine Meyer, Neil Allen and Dennis O'Brien; 10. Tetrathiomolybdate
versus Trientine in the initial treatment of neurologic Wilson's disease
George J. Brewer, Fred Askari, Matthew T. Lorincz, Martha Carlson, Michael
Schilsky, Karen J. Kluin, Peter Hedera, Paolo Moretti, John K. Fink,
Roberta Tankanow, Robert B. Dick and Julia Sitterly; 11. Randomized
clinical trials of Pregabalin for neuropathic pain: methods, results, and
implications Robert H. Dworkin, Rajbala Thakur, Teresa Griesing, Uma Sharma
and James P. Young; 12. Effect of Methylphenidate in patients with acute
traumatic brain injury: a randomized clinical trial Hossein A. Khalili and
Kamyar Keramatian; 13. Improvement in speeded cognitive processing after
anti-epileptic drug withdrawal - a controlled study in mono-therapy
patients Erik Hessen, Morten I. Lossius, Ivar Reinvang and Leif Gjerstad;
14. A randomized-controlled trial of bilateral rTMS for treatment-resistant
depression Paul B. Fitzgerald; 15. Serotonin related genes affect
antidepressant treatment in obsessive-compulsive disorder F. Van
Nieuwerburgh, D. Deforce and D. A. J. P. Denys; 16. Night eating syndrome
and results from the first placebo-controlled trial of treatment, with the
SSRI medication, Sertraline: implications for clinical practice John P.
O'Reardon Karen E. Groff, Albert J. Stunkard and Kelly C. Allison; 17.
Modafinil: a candidate for pharmacotherapy of negative symptoms in
schizophrenia John H. Peloian and Joseph M. Pierre; 18. New approaches to
treatment of schizophrenia by enhancing N-methyl-D-aspartate
neurotransmission Guochuan Emil Tsai; Subject index; Author index.